Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial

Autor: Sarfaraz Sayyed, R. Paul Aftring, Nathalie Alos, Leanne M Ward, Mikhail Kostik, Ekaterina Alexeeva, Anne Marie Sbrocchi, Nazih Shenouda, Kebashni Thandrayen, Craig F Munns, Gangadhar Sunkara, Nick Shaw, Jacob L. Jaremko, David A. Cabral, Éva Hosszú, Shayne Taback, Celia Rodd, Raja Padidela, Anup Choudhury

Publikováno v: The Journal of clinical endocrinology and metabolism. 106(12)

Context Glucocorticoids (GCs) prescribed for chronic pediatric illnesses are associated with osteoporotic fractures. Objective This study aims to determine the efficacy and safety of intravenous (IV) zoledronic acid (ZA) compared with placebo to trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e62d7081ad1ef4462d69bec9a36927ea
https://pubmed.ncbi.nlm.nih.gov/34228102

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON‐Pivotal Fracture Trial (PFT)

Autor: Dennis M. Black, Ian R. Reid, Jane A. Cauley, Felicia Cosman, Ping Chung Leung, Peter Lakatos, Kurt Lippuner, Steven R. Cummings, Trisha F. Hue, Amitava Mukhopadhyay, Monique Tan, R. Paul Aftring, Richard Eastell

Publikováno v: Black, Dennis M.; Reid, Ian R.; Cauley, Jane A.; Cosman, Felicia; Leung, Ping Chung; Lakatos, Peter; Lippuner, Kurt; Cummings, Steven R.; Hue, Trisha F.; Mukhopadhyay, Amitava; Tan, Monique; Aftring, R. Paul; Eastell, Richard (2015). The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of bone and mineral research, 30(5), pp. 934-944. Wiley-Blackwell 10.1002/jbmr.2442

While bisphosphonates reduce fracture risk over 3 to 5 years, the optimal duration of treatment is uncertain. In a randomized extension study (E1) of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c00d6d57adc0e49d8f0f7304c9a940
https://doi.org/10.1002/jbmr.2442

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

Autor: John M, Lachin, Giancarlo, Viberti, Bernard, Zinman, Steven M, Haffner, R Paul, Aftring, Gitanjali, Paul, Barbara G, Kravitz, William H, Herman, Rury R, Holman, Steven E, Kahn

Publikováno v: Clinical Journal of the American Society of Nephrology. 6:1032-1040

BACKGROUND AND OBJECTIVES: In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we exam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc49e31caa3db266992f86a46285635
https://doi.org/10.2215/cjn.09291010

Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation

Autor: R. Paul Aftring, Monique Tan, Joseph R. Tucci, Henry G. Bone, Guoqin Su, Zafer E. Ozturk

Publikováno v: Therapeutic Advances in Endocrinology and Metabolism, Vol 6 (2015)

Objective: Bisphosphonates are the most effective therapeutic agents in patients with Paget’s disease of bone. As a result of their inhibition of osteoclastic activity, hypocalcemia of variable frequency and severity following intravenous bisphosph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97bf0868d207b462805b2eb7d74c2b2
https://pubmed.ncbi.nlm.nih.gov/26301065

Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study

Autor: R. Paul Aftring, José Andrés Román Ivorra, Naomi S. Levitt, Oscar Antunez-Flores, Jacques P. Brown, Ian L. Ross, Javier Bachiller-Corral, Ian R. Reid, Guoqin Su

Publikováno v: BoneKEy Reports. 2

Six patients from the phase 3 trials of zoledronic acid in Paget's disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d042e6b029d850814bdbbb669d3e202
https://doi.org/10.1038/bonekey.2013.176